Influence of serum progesterone levels at the time of hCG on the release of ova during hMG cycles.
A study was designed to monitor release of ova by sonography in hMG-treated patients following hCG and to determine if failure to release ova correlates with critically low or high progesterone levels. This was a retrospective study of 292 consecutive patients treated with hMG. The requirement for treatment was that hCG be given when at least one follicle attained a 17-mm diameter with a serum estradiol level of at least 200 pg/mL per mature follicle. If the serum progesterone assay was greater than or equal to 1.8 ng/mL, then hCG would be given as long as there was at least one dominant follicle and a serum estradiol level greater than 200 pg/mL. The patients were divided into four groups for study based on the progesterone level at the time of hCG administration. There were no statistically significant differences in the ability to achieve ova release whether serum progesterone was very low or close to 2 ng/mL when hCG was given. The rise in the progesterone level prior to ovulation has been proposed to enhance egg release. However, the data presented herein do not support the necessity for a critical level of serum progesterone at the time of hCG injection in hMG-treated women.
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden.
J H
JH
Check
H G
HG
Adelson
J
J
Stern
C
C
Lauer
D000858:Anovulation / Q000188:drug therapy*; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008596:Menotropins / Q000008:administration & dosage / Q000627:therapeutic use*; D010060:Ovulation / Q000502:physiology*; D010062:Ovulation Induction; D011374:Progesterone / Q000097:blood*; D012189:Retrospective Studies
D006063:Chorionic Gonadotropin; D011374:Progesterone; D008596:Menotropins